Abstract
Abstract Gastric cancer is not a top‐10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard‐of‐care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD‐L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein‐Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.
Keywords
MedicineCancerImmunotherapyMalignancyOncologyMicrosatellite instabilityTargeted therapyRadiation therapyChemotherapyAdenocarcinomaInternal medicineDiseaseTrastuzumabImmunologyBiologyBreast cancer
MeSH Terms
AdenocarcinomaAngiogenesis InhibitorsAntineoplastic AgentsImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiomarkersTumorChemoradiotherapyAdjuvantChemotherapyAdjuvantDNA Mismatch RepairEsophagogastric JunctionGastrectomyHumansImmune Checkpoint InhibitorsMicrosatellite InstabilityMutationNeoadjuvant TherapyNeoplasm RecurrenceLocalNeoplasm StagingReceptorErbB-2Stomach Neoplasms
Affiliated Institutions
Related Publications
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifyi...
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic l...
Prognostic value of microsatellite instability in resectable pancreatic cancer.
The significance of microsatellite instability (MSI) as a prognostic predictor for resectable pancreatic cancer patients was examined. Forty-six histologically confirmed pancrea...
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Abstract We examined the immune microenvironment of primary colorectal cancer using immunohistochemistry, laser capture microdissection/qRT-PCR, flow cytometry, and functional a...
Immunotherapy in colorectal cancer: rationale, challenges and potential
Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a su...
Publication Info
- Year
- 2021
- Type
- review
- Volume
- 71
- Issue
- 3
- Pages
- 264-279
- Citations
- 1647
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1647
OpenAlex
33
Influential
Cite This
Smita S. Joshi,
Brian D. Badgwell
(2021).
Current treatment and recent progress in gastric cancer.
CA A Cancer Journal for Clinicians
, 71
(3)
, 264-279.
https://doi.org/10.3322/caac.21657
Identifiers
- DOI
- 10.3322/caac.21657
- PMID
- 33592120
- PMCID
- PMC9927927